KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer

► KRC-408 is a novel triazolopyridazine derivative that targets the catalytic activity of c-Met. ► KRC-408 has a significant effect on cancer cells expressing c-Met by blocking the c-Met signaling pathway. ► KRC-408 inhibited cell proliferation, angiogenesis as well as induction of apoptosis in cases of gastric cancer. ► KRC-408 is a novel therapeutic candidate effective against gastric cancers that overexpress c-Met.